Details werden geladen...
ADA in 30 Seconds: Triple-G safety data, a monthly obesity drug, and more | STAT
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
Ähnliche Seiten
ADA in 30 Seconds: Competition for obesity drugs, clinical blind spots, and more | STAT
https://www.statnews.com/2026/06/07/competition-obesity-drugs-clinical-blind-spots-and-more-ada/ADA in 30 Seconds: Newer GLP-1s, pushback on research cuts, and a protest | STAT
https://www.statnews.com/2026/06/05/newer-glp-1s-pushback-on-research-cuts-and-a-protest-ada-in-30/Lilly shares safety, tolerability data on its next-gen obesity drug | STAT
https://www.statnews.com/2026/06/06/illy-retatrutide-triple-g-weight-loss-obesity-safety-data-ada/New data cast doubt on competitiveness of Boehringer’s obesity drug | STAT
https://www.statnews.com/2026/06/07/boehringer-ingelheim-obesity-drug-survodutide-phase-3-data/Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
https://www.statnews.com/pharmalot/2026/06/08/lilly-pfizer-obesity-drug-trial-data-roche-deal/